U.S. FDA Sends Warning Letter To Ozempen.com; FDA Observed That Introduces Into Interstate Commerce Unapproved And Misbranded Semaglutide Drug Products; Requests Cease Offering Any Unapproved And Misbranded Drugs For Sale To U.S. Consumers
U.S. FDA Sends Warning Letter To Ozempen.com; FDA Observed That Introduces Into Interstate Commerce Unapproved And Misbranded Semaglutide Drug Products; Requests Cease Offering Any Unapproved And Misbranded Drugs For Sale To U.S. Consumers
美國食品藥品監督管理局給Ozempen.com發送了警告信; FDA發現其將未經批准和標籤錯誤的Semaglutide藥品引入州際商業; 要求停止向美國消費者銷售任何未經批准和標籤錯誤的藥品。
U.S. FDA Sends Warning Letter To Ozempen.com; FDA Observed That Introduces Into Interstate Commerce Unapproved And Misbranded Semaglutide Drug Products; Requests Cease Offering Any Unapproved And Misbranded Drugs For Sale To U.S. Consumers
美國食品藥品監督管理局給Ozempen.com發送了警告信; FDA發現其將未經批准和標籤錯誤的Semaglutide藥品引入州際商業; 要求停止向美國消費者銷售任何未經批准和標籤錯誤的藥品。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。